Display options
Cite
Lip PL, Malick H, Damer K, et al. One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK. Clin Ophthalmol. 2015;9:1779-84doi: 10.2147/OPTH.S89147.
Lip, P. L., Malick, H., Damer, K., Elsherbiny, S., Darrad, K. M., Mushtaq, B., Mitra, A., Stavrou, P., & Yang, Y. (2015). One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK. Clinical ophthalmology (Auckland, N.Z.), 91779-84. https://doi.org/10.2147/OPTH.S89147
Lip, Peck Lin, et al. "One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK." Clinical ophthalmology (Auckland, N.Z.) vol. 9 (2015): 1779-84. doi: https://doi.org/10.2147/OPTH.S89147
Lip PL, Malick H, Damer K, Elsherbiny S, Darrad KM, Mushtaq B, Mitra A, Stavrou P, Yang Y. One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK. Clin Ophthalmol. 2015 Sep 25;9:1779-84. doi: 10.2147/OPTH.S89147. eCollection 2015. PMID: 26445525; PMCID: PMC4590638.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2015 Sep 25;9:1779-84. doi: 10.2147/OPTH.S89147. eCollection 2015.

One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK.

Clinical ophthalmology (Auckland, N.Z.)

Peck Lin Lip, Huzaifa Malick, Kenan Damer, Samer Elsherbiny, Kanupriya M Darrad, Bushra Mushtaq, Arijit Mitra, Panagiota Stavrou, Yit Yang

Affiliations

  1. Birmingham and Midland Eye Centre, City Hospital, Aston University, Birmingham, UK.
  2. Birmingham and Midland Eye Centre, City Hospital, Aston University, Birmingham, UK ; School of Health and Life Sciences, Aston University, Birmingham, UK.

PMID: 26445525 PMCID: PMC4590638 DOI: 10.2147/OPTH.S89147

Abstract

BACKGROUND: The purpose of this study was to investigate the 12-month outcome of macular edema secondary to both chronic and new central and branch retinal vein occlusions treated with intravitreal bevacizumab in the real-life clinical setting in the UK.

METHODS: Retrospective case notes analysis of consecutive patients with retinal vein occlusions treated with bevacizumab in 2010 to 2012. Outcome measures were visual acuity (measured with Snellen, converted into logMAR [logarithm of the minimum angle of resolution] for statistical calculation) and central retinal thickness at baseline, 4 weeks post-loading phase, and at 1 year.

RESULTS: There were 56 and 100 patients with central and branch retinal vein occlusions, respectively, of whom 62% had chronic edema and received prior therapies and another 32% required additional laser treatments post-baseline bevacizumab. Baseline median visual acuity was 0.78 (interquartile range [IQR] 0.48-1.22) in the central group and 0.6 (IQR 0.3-0.78) in the branch group. In both groups, visual improvement was statistically significant from baseline compared to post-loading (P<0.001 and P=0.03, respectively), but was not significant by month 12 (P=0.058 and P=0.166, respectively); 30% improved by at least three lines and 44% improved by at least one line by month 12. Baseline median central retinal thickness was 449 μm (IQR 388-553) in the central group and 441 μm (IQR 357-501) in the branch group. However, the mean reduction in thickness was statistically significant at post-loading (P<0.001) and at the 12-month time point (P<0.001) for both groups. The average number of injections in 1 year was 4.2 in the central group and 3.3 in the branch group.

CONCLUSION: Our large real-world cohort results indicate that bevacizumab introduced to patients with either new or chronic edema due to retinal vein occlusion can result in resolution of edema and stabilization of vision in the first year.

Keywords: chronic; laser; loading dose; risk factors; subretinal fluid

References

  1. Ophthalmology. 2010 Jun;117(6):1124-1133.e1 - PubMed
  2. Ophthalmology. 2010 Jun;117(6):1113-1123.e15 - PubMed
  3. Retina. 2007 Apr-May;27(4):419-25 - PubMed
  4. Clin Ter. 2012 Nov;163(6):e413-22 - PubMed
  5. Ophthalmology. 2011 Dec;118(12):2453-60 - PubMed
  6. Arch Ophthalmol. 1996 Oct;114(10):1243-7 - PubMed
  7. Ophthalmology. 2012 Oct;119(10):2108-18 - PubMed
  8. Ophthalmology. 2015 Jan;122(1):146-52 - PubMed
  9. J Ophthalmic Vis Res. 2014 Oct-Dec;9(4):461-8 - PubMed
  10. Ophthalmology. 2012 Dec;119(12):2587-91 - PubMed
  11. Am J Ophthalmol. 2014 Nov;158(5):1032-8 - PubMed
  12. BMJ. 2012 Aug 13;345:e5182 - PubMed
  13. Br J Ophthalmol. 2013 Nov;97(11):1447-50 - PubMed
  14. Br J Ophthalmol. 2015 Jul;99(7):954-9 - PubMed
  15. Lancet. 2013 Oct 12;382(9900):1258-67 - PubMed
  16. Am J Ophthalmol. 2013 Sep;156(3):502-10.e2 - PubMed
  17. Br J Ophthalmol. 2014 Feb;98(2):195-9 - PubMed
  18. Ophthalmology. 2014 Jul;121(7):1414-1420.e1 - PubMed
  19. Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81-7 - PubMed
  20. Ophthalmology. 2014 Jan;121(1):209-19 - PubMed
  21. Retina. 2010 Jul-Aug;30(7):1046-50 - PubMed
  22. N Engl J Med. 2015 Mar 26;372(13):1193-203 - PubMed
  23. Ophthalmology. 2012 Apr;119(4):802-9 - PubMed
  24. Retina. 2014 Aug;34(8):1637-43 - PubMed
  25. Ophthalmology. 2010 Feb;117(2):313-9.e1 - PubMed
  26. Ophthalmology. 2012 Jul;119(7):1388-98 - PubMed

Publication Types